NCT02761057 Randomized Phase 2 assessment of MET inhibitors in metastatic PRCC

Start/End Date 
May 3, 2016 to November 3, 2016
Cancer Types 
Sunitinib, Volitinib
Phase 2

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.